Subtype
Urinary Tract Carcinoma
CI-CAN-00007014Explore in graph →
326 active trials11 approved drugs23 evidence items
- NCIt
- C192669
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007014Explore in graph →
Clinical trials
852 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors(INSIGHT) | active not recruiting | Phase 1 | 83 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | active not recruiting | Phase 2 | 6 | Emory UniversityOTHER | 1 |
| Feb 19, 2026 |
| clinicaltrials |
| NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma(IMPROEV) | recruiting | Phase 2 | 97 | Fox Chase Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 47 | University of California, San FranciscoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Feb 18, 2026 | clinicaltrials |
| NCT06138561 | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | recruiting | — | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07412171 | NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC(NECTAR) | not yet recruiting | Phase 2 | 40 | Peking University Third HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07395037 | A Study of Ward Admissions for Haematuria(WASHOUT) | recruiting | — | 1,050 | British Urology Researchers in Surgical TrainingOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07183319 | Circulating Tumor DNA Response In Urothelial Cancer | recruiting | Phase 2 | 30 | University of OklahomaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07374549 | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 100 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04623502 | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339761 | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study(SPICE) | recruiting | N/A | 30 | University of AarhusOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339878 | Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma(FLORAL) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT07334314 | Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs(OUAF) | recruiting | — | 340 | University Hospital, Strasbourg, FranceOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02989584 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | recruiting | Phase 1 | 96 | Dren BioINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07314723 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | recruiting | Phase 2 | 90 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06120374 | Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC | recruiting | — | 178 | Peking University First HospitalOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07077447 | The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract(EuroCUT) | recruiting | — | 2,500 | Zealand University HospitalOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT04863885 | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | active not recruiting | Phase 1 / Phase 2 | 46 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06263153 | Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy | recruiting | Phase 2 | 24 | Yuanquan YangOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06129084 | A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing | active not recruiting | — | 260 | Bernie EiglOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06210490 | A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery | recruiting | Phase 2 | 60 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT05912816 | Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | recruiting | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05768347 | Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | active not recruiting | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06537960 | Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers(TARDITEP) | recruiting | N/A | 66 | Hopital FochOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07037589 | Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?(BLUSH) | recruiting | — | 300 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04428554 | Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy(BLAD-RAD01) | recruiting | Phase 2 | 130 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06218433 | Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study) | recruiting | N/A | 200 | Tampere University HospitalOTHER | 2 | Nov 18, 2025 | clinicaltrials |
| NCT06190197 | Prophylactic Antibiotics in Cystectomy With Diversion | recruiting | Early Phase 1 | 120 | University of MinnesotaOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02735252 | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | active not recruiting | N/A | 156 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02420847 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2026source: clinicaltrials